The Health and Medical Education Authority at the Imam Hussain Holy Shrine has announced plans to make one of the world's most advanced gene therapies for hemophilia (inherited bleeding disorder) available in Iraq by (2029). The authority noted that the treatment is currently the world's most expensive, costing approximately (3.5) million US dollars per dose.
Speaking to the official website, the Head of the Authority, Dr. Haider Hamza Al-Abadi, said, "The Health and Medical Education Authority at the Imam Hussain Holy Shrine is working to provide one of the latest innovative gene therapies for hemophilia (inherited bleeding disorder) patients in Iraq by (2029)," noting that "this treatment is the most expensive in the world, with a cost of approximately (3.5) million US dollars per dose."
He explained that "the therapy, developed by the Australian company (CSL) through its research centers in Germany, the United States, and Switzerland, is based on direct gene therapy technology that restores the body's ability to produce the clotting factor."
He added that "the high global cost of this treatment will not stand in the way of including Iraq among the countries that will benefit from it." He pointed out that "establishing early timelines will ensure that patients receive the treatment and all of their healthcare needs within the specified timeframe."
This initiative is part of the ongoing efforts of the General Secretariat of the Imam Hussain Holy Shrine, through its Health and Medical Education Authority, to advance specialized healthcare services and elevate medical care in Iraq from merely controlling symptoms to providing definitive treatments that end the long-term suffering of patients while reducing the need to travel abroad for treatment.
اترك تعليق